This contract will provide for the production, scale-up, characterization and formulation of specific vaccine antigens and reagents as directed by the NIAID. In addition pilot lots of candidate vaccines will be produced under GLP/cGMPs appropriate for Phase I and Phase II human clinical trials.
|Effective start/end date||6/30/99 → 7/13/24|
- National Institutes of Health: $224,563.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.